Skip to main content
. Author manuscript; available in PMC: 2014 Jun 17.
Published in final edited form as: Am J Med Sci. 2014 Feb;347(2):167–169. doi: 10.1097/MAJ.0000000000000243

FIGURE 1.

FIGURE 1

(A) Graph of the patient’s platelet levels just before and after bevacizumab-FOLFIRI administration was resumed. Testing of patient’s serum for drug-dependent platelet antibodies by flow cytometry assay showed strong IgG antibody reactivity (MFI = 577.3) in the patient’s acute serum only in the presence of irinotecan (B) (dark histogram), but not with normal control serum and drug (C) (dark histogram). MFI = median fluorescence intensity.